Supplemental Material:  Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Brenna L. Brady, PhD;Lucci,Matthew;Wilson,Kathleen;Kathleen M. Fox, PhD;Wojtynek,Jeffrey;Cooper,Chelsea;Varker,Helen;Chebili,Christina;Igoni Dokubo, MD;

Publication

Peer-Reviewed

December 23, 2020

Evidence-Based Oncology

January 2021

Volume27

Issue 1

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Author(s):

Brenna L. Brady, PhD,Matthew Lucci, MPH

Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.

eAPPENDIX Clinical and Economic Burden of Intravenous Paclitaxel

Articles in this issue

ASH 2020: Clinical Updates

ASH 2020: COVID-19 and Hematology

ASH 2020: CAR T-Cell Therapy Updates

ASH 2020: The Next Wave

2020 SABCS: Topics in Precision Oncology

Lauren M. Corduck, Founder of Oneinforty, Dies at 49; Advocated for Change in BRCA Testing Guidelines

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Newsletter